Magnolia Capital Advisors LLC Takes $461,000 Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Magnolia Capital Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 6,720 shares of the biopharmaceutical company’s stock, valued at approximately $461,000.

A number of other hedge funds also recently made changes to their positions in GILD. Gilbert & Cook Inc. grew its holdings in shares of Gilead Sciences by 5.3% in the 4th quarter. Gilbert & Cook Inc. now owns 6,791 shares of the biopharmaceutical company’s stock worth $550,000 after purchasing an additional 344 shares during the last quarter. Aveo Capital Partners LLC grew its holdings in shares of Gilead Sciences by 8.6% in the 4th quarter. Aveo Capital Partners LLC now owns 5,473 shares of the biopharmaceutical company’s stock worth $443,000 after purchasing an additional 435 shares during the last quarter. J. W. Coons Advisors LLC grew its holdings in shares of Gilead Sciences by 2.8% in the 4th quarter. J. W. Coons Advisors LLC now owns 11,130 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 300 shares during the last quarter. Evoke Wealth LLC bought a new stake in shares of Gilead Sciences in the 4th quarter worth about $204,000. Finally, Rathbones Group PLC grew its holdings in shares of Gilead Sciences by 3.7% in the 4th quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock worth $339,000 after purchasing an additional 150 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GILD shares. Truist Financial upped their target price on shares of Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Piper Sandler reaffirmed an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a report on Wednesday, September 11th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective on the stock in a report on Monday, July 8th. Robert W. Baird reissued a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a report on Thursday, June 20th. Finally, Evercore ISI raised shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.06.

Insider Activity

In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $83.84 on Tuesday. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $87.86. The firm’s 50 day moving average price is $78.28 and its two-hundred day moving average price is $71.60. The firm has a market cap of $104.45 billion, a P/E ratio of 232.89, a PEG ratio of 2.91 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. On average, analysts forecast that Gilead Sciences, Inc. will post 3.78 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were issued a $0.77 dividend. The ex-dividend date was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.67%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.